A safe and effective Ebola vaccine
Based on the technology behind the well-known measles vaccine
The goal of this project is to build on the existing vaccine against measles to rapidly produce an Ebola vaccine.
Currently there is no clinically proven preventive vaccine against Ebola. By building on one of the safest and most efficient vaccines that exist today, Institut Pasteur’s scientists aim to develop a vaccine that induces long-lasting immunity against Ebola. By using this method, a safe and effective vaccine can rapidly be ready for testing and production.
Institut Pasteur has assigned two of the world’s top experts, Sylvain Baize and Frederic Tangy, to solve this challenge. The team and its expertise will allow Institut Pasteur to rapidly generate an effective vaccine on Ebola.
Because of the use of existing vaccine technology this vaccine can be ready for clinical trials and production within only a few months.
Institut Pasteur has chosen to develop the Ebola vaccine based on the technology behind the measles vaccine because it is one of the safest and most efficient vaccines today. Measles vaccines has been administered to billions of children over the last 40 years.
The measles vaccine is produced on a large scale around the world and is distributed at low cost through the WHO Expanded Program on Immunization.
The measles technology-based vaccines can be used to make children immune to measles and other infections at the same time. According to a recent clinical trial, they can also be given to adults with pre-existing immunity to measles. Other vaccines that are being developed on the basis of the measles vaccine include HIV, Malaria, RSV, SARS and Dengue.
Based on this model, Institute Pasteur will test three Ebola vaccines. They will build on Institut Pasteur’s expertise on Ebola in particular, as well as virology, immunology and vaccine development in general.
Dr. Frederic Tangy,
Head of Viral Genomics and Vaccination laboratory
Dr. Sylvain Baize,
Head of Unit of the Emerging Infections
Dr James Philip Di Santo,
Head of the Innate Immunity Unit